Multiplex high-throughput gene mutation analysis in acute myeloid leukemia

Human Pathology

Volumn 43, Issue 12, 2012, Pages 2167-2176

  Dunlap, Jennifer ^a   Beadling, Carol ^a,b   Warrick, Andrea ^b   Neff, Tanaya ^b   Fleming, William H ^a,b,c   Loriaux, Marc ^a,b   Heinrich, Michael C ^a,b,d   Kovacsovics, Tibor ^a,b   Kelemen, Katalin ^a   Leeborg, Nicky ^a   Gatter, Ken ^a   Braziel, Rita M ^a,b   Press, Richard ^a,b   Corless, Christopher L ^a,b   Fan, Guang ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Gene mutation; Genetics; Molecular

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CEBPA GENE; CHROMOSOME ABERRATION; CYTOGENETICS; DNA SEQUENCE; FEMALE; FLT3 GENE; FLT3 ITD GENE; GENE MUTATION; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; IDH1 GENE; KARYOTYPE; KIT GENE; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; NPM1 GENE; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; POINT MUTATION; PTPN11 GENE;

CCAAT-ENHANCER-BINDING PROTEINS; DNA MUTATIONAL ANALYSIS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; TUMOR MARKERS, BIOLOGICAL;

EID: 84869497111     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.03.002     Document Type: Article

References (24)

1. L.M. Kelly, and D.G. Gilliland Genetics of myeloid leukemias Annu Rev Genomics Hum Genet 3 2002 179 198
2. B.L. Betz, and J.L. Hess Acute myeloid leukemia diagnosis in the 21st century Arch Pathol Lab Med 134 2010 1427 1433
3. R.E. Gale, C. Green, and C. Allen The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia Blood 111 2008 2776 2784
4. R.F. Schlenk, K. Dohner, and J. Krauter Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 2008 1909 1918
5. A. Tefferi, K.H. Lim, and O. Abdel-Wahab Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML Leukemia 23 2009 1343 1345
6. T.J. Ley, L. Ding, and M.J. Walter DNMT3A mutations in acute myeloid leukemia N Engl J Med 363 2010 2424 2433
7. E.R. Mardis, L. Ding, and D.J. Dooling Recurring mutations found by sequencing an acute myeloid leukemia genome N Engl J Med 361 2009 1058 1066
8. G. Marcucci, T. Haferlach, and H. Dohner Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications J Clin Oncol 29 2011 475 486
9. H. Dohner, E.H. Estey, and S. Amadori Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood 115 2010 453 474
10. C. Beadling, M.C. Heinrich, and A. Warrick Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry J Mol Diagn 13 2011 504 513
11. T. Pabst, M. Eyholzer, and J. Fos Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis Br J Cancer 100 2009 1343 1346
12. L.E. MacConaill, C.D. Campbell, and S.M. Kehoe Profiling critical cancer gene mutations in clinical tumor samples PLoS One 4 2009 e7887
13. R.K. Thomas, A.C. Baker, and R.M. Debiasi High-throughput oncogene mutation profiling in human cancer Nat Genet 39 2007 347 351
14. P.A. Ho, T.A. Alonzo, and K.J. Kopecky Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study Leukemia 24 2010 909 913
15. K.P. Patel, F. Ravandi, and D. Ma Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features Am J Clin Pathol 135 2011 35 45
16. S. Schnittger, C. Haferlach, and M. Ulke IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status Blood 116 2010 5486 5496
17. P. Paschka, R.F. Schlenk, and V.I. Gaidzik IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication J Clin Oncol 28 2010 3636 3643
18. F. Damm, M. Heuser, and M. Morgan Integrative prognostic risk score in acute myeloid leukemia with normal karyotype Blood 117 2011 4561 4568
19. V. Rockova, S. Abbas, and B.J. Wouters Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers Blood 118 2011 1069 1076
20. Y. Shen, Y.M. Zhu, and X. Fan Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia Blood 118 2011 5593 5603
21. L.Y. Shih, C.F. Huang, and P.N. Wang Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia Leukemia 18 2004 466 475
22. U. Bacher, T. Haferlach, and C. Schoch Implications of NRAS mutations in AML: a study of 2502 patients Blood 107 2006 3847 3853
23. D.T. Bowen, M.E. Frew, and R. Hills RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years Blood 106 2005 2113 2119
24. M.K. Kiessling, P.A. Oberholzer, and C. Mondal High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade Blood 117 2011 2433 2440